Job Ref: NBC/25/09
Salary: £36,000 - £46,000 pa (depending upon experience)
Duration: Permanent
About the role
The goal of the CRUK National Biomarker Centre (NBC) is to develop, validate, and implement biomarkers that facilitate the optimisation of cancer patient treatment. In this regard, the NBC is an acknowledged world leader in the study of minimally invasive biomarkers, or liquid biopsies, for improving cancer management. Our biomarker research integrates clinical, experimental, and computational science into a highly convergent programme. Translational research and clinical implementation is critical to this biomarker agenda.
An exciting opportunity has arisen for a Senior Translational Scientist to join the Nucleic Acids Biomarker (NAB) team of the NBC. You will lead and coordinate the efforts of the NAB team in translational research, working alongside a multidisciplinary team of biologists, clinicians, computational scientists, and engineers. The NAB team is developing new targeted and genome-wide sequencing methods (e.g. mutation, methylation, fragmentomics, transcriptomics) and molecular assays (e.g. ddPCR), generating complex sets of data from liquid biopsy samples. These methods are employed across the NAB translational portfolio, which includes projects across a range of solid and haematological cancers in collaborations with clinicians, biotech, pharma, and academia.
About you:
You will have a degree in cancer genomics or molecular biology (or equivalent relevant degree) plus extensive relevant experience. A relevant MSc with equivalent level of experience in academia or industry is desirable.
You will have extensive experience in the development, validation, implementation, and reporting of clinical and translational biomarker assays for clinical studies. You will be experienced with the management and administration relating to handling and banking of clinical trial samples and liaison with relevant external organisations, for example, clinical trial sponsors and trial co-ordinators, aiming to work towards GCP. An understanding of liquid biopsies, cancer genomics, and/or cancer biology is desirable, as is an understanding of bioinformatics analysis of NGS data. Experience of multidisciplinary teamwork will be essential. You will have strong communication skills and a desire to work collaboratively with scientists from other disciplines.
Why choose Cancer Research UK National Biomarker Centre?
The Cancer Research UK National Biomarker Centre (https://cruknbc.org/) is a leading and highly specialised translational research centre within The University of Manchester, aligned with the Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk), and core-funded by Cancer Research UK (www.cancerresearchuk.org), the largest independent cancer research organisation in the world. In spring 2023, the Institute moved into the state-of-the-art Paterson Building, a £150 million flagship purpose-built biomedical research centre directly attached to The Christie NHS Foundation Trust in South Manchester (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational, and clinical research programmes.
Our Centre discovers, develops, validates, and qualifies biomarkers in clinical studies and trials that detect cancer earlier and predict and monitor therapy responses to support optimised treatment of patients with cancer. Our advanced research programmes, agnostic to cancer type, develop biomarkers in tissue and less invasive clinical samples such as blood (liquid biopsy) with sophisticated bioinformatic and artificial intelligence solutions for multi-modal laboratory and clinical biomarker data analysis and interpretation. As a bridge between discovery science and clinical research, we are highly collaborative across Manchester, nationally and internationally.
To apply visit: https://cruknbc.org/news/
For informal enquiries, contact Dr Florent Mouliere at: florent.mouliere@cruk.manchester.ac.uk
Deadline for applications: 9 March 2025.
#J-18808-Ljbffr